Pharmacogenomic biomarkers do not predict response to drotrecogin alfa in patients with severe sepsis

PURPOSE: To explore potential design for pharmacogenomics trials in sepsis, we investigate the interaction between pharmacogenomic biomarkers and response to drotrecogin alfa (activated) (DrotAA). This trial was designed to validate whether previously identified improved response polymorphisms (IRPs...

Descripción completa

Detalles Bibliográficos
Autores principales: Annane, Djillali, Mira, Jean-Paul, Ware, Lorraine B., Gordon, Anthony C., Hinds, Charles J., Christiani, David C., Sevransky, Jonathan, Barnes, Kathleen, Buchman, Timothy G., Heagerty, Patrick J., Balshaw, Robert, Lesnikova, Nadia, de Nobrega, Karen, Wellman, Hugh F., Neira, Mauricio, Mancini, Alexandra D. J., Walley, Keith R., Russell, James A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5792380/
https://www.ncbi.nlm.nih.gov/pubmed/29388048
http://dx.doi.org/10.1186/s13613-018-0353-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5792380/
https://www.ncbi.nlm.nih.gov/pubmed/29388048
http://dx.doi.org/10.1186/s13613-018-0353-2

Ejemplares similares